Group One Trading
KPTI icon

Group One Trading’s Karyopharm Therapeutics KPTI Stock Holding History

Group One Trading’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
191,527
+89,108
+87% +$679K ﹤0.01% 2646
2025
Q4 		$754K Buy
102,419
+33,983
+50% +$208K ﹤0.01% 3146
2025
Q3 		$448K Sell
68,436
-29,464
-30% -$159K ﹤0.01% 3815
2025
Q2 		$422K Buy
+97,900
New +$480K ﹤0.01% 3587
2024
Q2 		– Sell
-2,475
Closed -$41K – 7116
2024
Q1 		$56.1K Buy
2,475
+443
+22% +$7.77K ﹤0.01% 4625
2023
Q4 		$26.4K Sell
2,032
-1,602
-44% -$21.6K ﹤0.01% 5534
2023
Q3 		$73K Buy
3,634
+3,534
+3,534% +$79.3K ﹤0.01% 4747
2023
Q2 		$2.67K Sell
100
-107
-52% -$4.61K ﹤0.01% 6991
2023
Q1 		$12.1K Buy
+207
New +$10.2K ﹤0.01% 5835
2022
Q1 		– Sell
-8,008
Closed -$998K – 8355
2021
Q4 		$772K Buy
8,008
+4,898
+157% +$488K ﹤0.01% 3622
2021
Q3 		$272K Buy
3,110
+2,791
+875% +$290K ﹤0.01% 4845
2021
Q2 		$49K Sell
319
-3,231
-91% -$469K ﹤0.01% 6592
2021
Q1 		$560K Sell
3,550
-2,081
-37% -$438K ﹤0.01% 3891
2020
Q4 		$1.31M Buy
5,631
+4,136
+277% +$958K ﹤0.01% 2407
2020
Q3 		$327K Buy
+1,495
New +$366K ﹤0.01% 3237
2019
Q4 		– Sell
-2,443
Closed -$530K – 5362
2019
Q3 		$353K Buy
2,443
+1,863
+321% +$253K ﹤0.01% 2631
2019
Q2 		$52K Sell
580
-1,406
-71% -$113K ﹤0.01% 3749
2019
Q1 		$174K Buy
+1,986
New +$220K ﹤0.01% 2798
2018
Q2 		– Sell
-550
Closed -$136K – 5291
2018
Q1 		$111K Buy
+550
New +$110K ﹤0.01% 3181
2016
Q3 		– Sell
-504
Closed -$60.6K – 4718
2016
Q2 		$51K Buy
504
+281
+126% +$36.5K ﹤0.01% 3294
2016
Q1 		$30K Sell
223
-1,311
-85% -$145K ﹤0.01% 3527
2015
Q4 		$305K Buy
1,534
+939
+158% +$203K ﹤0.01% 2190
2015
Q3 		$94K Sell
595
-218
-27% -$58.3K ﹤0.01% 3079
2015
Q2 		$332K Buy
813
+306
+60% +$132K ﹤0.01% 2141
2015
Q1 		$233K Buy
507
+367
+262% +$158K ﹤0.01% 2251
2014
Q4 		$79K Buy
140
+75
+115% +$42.6K ﹤0.01% 3034
2014
Q3 		$34K Buy
+65
New +$36.7K ﹤0.01% 3796

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Group One Trading's KPTI Position: Q1 2026 in Review

Group One Trading increased its Karyopharm Therapeutics (KPTI) stake by 87% in Q1 2026, buying an estimated $679K and bringing the position to 191,527 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

Group One Trading first reported a position in KPTI in Q3 2014 and has held it in 27 quarters since. The position peaked at $1.31M in Q4 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Group One Trading held 191,527 shares of Karyopharm Therapeutics worth $1.07M as of Q1 2026.
  • Group One Trading bought 89,108 Karyopharm Therapeutics shares in Q1 2026, an estimated $679K.
  • Karyopharm Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2646 holding.
  • Group One Trading first reported a position in Karyopharm Therapeutics in Q3 2014 and has held it in 27 quarters since.
  • Group One Trading's Karyopharm Therapeutics position peaked at $1.31M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.